KMDA Stock Overview
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kamada Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪18.84 |
| 52 Week High | ₪23.38 |
| 52 Week Low | ₪16.27 |
| Beta | 0.24 |
| 1 Month Change | -11.05% |
| 3 Month Change | -13.26% |
| 1 Year Change | 11.61% |
| 3 Year Change | -5.28% |
| 5 Year Change | -14.52% |
| Change since IPO | 43.27% |
Recent News & Updates
Kamada's (TLV:KMDA) Earnings Are Of Questionable Quality
Mar 14
Kamada Ltd. (TLV:KMDA) Held Back By Insufficient Growth Even After Shares Climb 29%
Dec 30Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This Year
Dec 22Recent updates
Kamada's (TLV:KMDA) Earnings Are Of Questionable Quality
Mar 14Kamada Ltd. (TLV:KMDA) Held Back By Insufficient Growth Even After Shares Climb 29%
Dec 30Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This Year
Dec 22Is Kamada (TLV:KMDA) Using Too Much Debt?
Jan 26We Discuss Why Kamada Ltd.'s (TLV:KMDA) CEO Compensation May Be Closely Reviewed
Dec 16Investors Who Bought Kamada (TLV:KMDA) Shares Five Years Ago Are Now Up 38%
Mar 01Is Kamada Ltd. (TLV:KMDA) Popular Amongst Insiders?
Feb 08Is Weakness In Kamada Ltd. (TLV:KMDA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Jan 21
Kamada Ltd. (TLV:KMDA) Shares Could Be 42% Below Their Intrinsic Value Estimate
Jan 03How Many Kamada Ltd. (TLV:KMDA) Shares Have Insiders Sold, In The Last Year?
Dec 15Are Kamada's (TLV:KMDA) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 29Shareholder Returns
| KMDA | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | -3.6% | -1.8% | -3.1% |
| 1Y | 11.6% | 4.7% | 9.5% |
Return vs Industry: KMDA exceeded the IL Biotechs industry which returned 4.7% over the past year.
Return vs Market: KMDA exceeded the IL Market which returned 9.5% over the past year.
Price Volatility
| KMDA volatility | |
|---|---|
| KMDA Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 8.0% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: KMDA has not had significant price volatility in the past 3 months.
Volatility Over Time: KMDA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 378 | Amir London | www.kamada.com |
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers.
Kamada Ltd. Fundamentals Summary
| KMDA fundamental statistics | |
|---|---|
| Market cap | ₪1.08b |
| Earnings (TTM) | ₪31.48m |
| Revenue (TTM) | ₪541.60m |
34.4x
P/E Ratio2.0x
P/S RatioIs KMDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KMDA income statement (TTM) | |
|---|---|
| Revenue | US$142.52m |
| Cost of Revenue | US$87.03m |
| Gross Profit | US$55.49m |
| Other Expenses | US$47.21m |
| Earnings | US$8.28m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 38.94% |
| Net Profit Margin | 5.81% |
| Debt/Equity Ratio | 0% |
How did KMDA perform over the long term?
See historical performance and comparison